No Data
Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval From China
Ge Long Hui announcement selection (Hong Kong stocks) | Guangzhou Automobile Group (02238.HK) March autos sales of 173,929 units, a year-on-year decrease of 3.01%.
【Today's Focus】Guangzhou Automobile Group (02238.HK) sold 173,929 Autos in March, a year-on-year decrease of 3.01%. Guangzhou Automobile Group (02238.HK) announced that the automobile production for March 2025 would be 188,863 units, an increase of 17.65% compared to the same period last year, with a cumulative production of 411,205 units this year, showing a growth of 2.09% year on year. The automobile sales in March 2025 were 173,929 units, a decrease of 3.01% compared to the same period last year, with a cumulative sales of 371,087 units this year, a decline of 9.42% year on year.
SINO BIOPHARM (01177.HK) "TQB6411 (EGFR/c-Met dual antibody ADC)" clinical trial application has been accepted by the CDE.
On April 3, Gelonghui reported that SINO BIOPHARM (01177.HK) announced that the group’s self-developed "TQB6411 (EGFR/c-Met dual antibody ADC)" has submitted a clinical trial application to the Drug Evaluation Center ("CDE") of the National Medical Products Administration of China and has been accepted. The epidermal growth factor receptor (EGFR) and the c-Met are two important driving genes of lung cancer, both belonging to receptor tyrosine kinases, and have a synergistic effect in downstream signaling transduction. Jointly targeting EGFR and c-Met can block the PI3K/
UBS Group: Raises Joinn Laboratories' Target Price to HKD 14.3, rating downgraded to 'Neutral'.
UBS Group released a Research Report stating that Joinn Laboratories (06127) performed roughly as expected last year, with a 15.1% year-on-year revenue decline and an 81.3% year-on-year net profit decrease. The firm has lowered its earnings per share forecasts for this year, next year, and 2027 by 1%, 15%, and 26% respectively. Its Target Price has been raised from HKD 12.6 to HKD 14.3, and its rating downgraded from "Buy" to "Neutral." The firm believes that the market has largely absorbed the recovery observed over the past few quarters, as reflected in the new subscription volume showing a quarter-on-quarter recovery last year and the non-human primates from the second to the fourth quarters last year.
Zhongtai: Innovative Drugs lead the market, pay attention to Q1 performance + policy catalysis.
In April, the pharmaceutical Sector is expected to continue its structural market trend, with Innovative Drugs as the main line and thematic opportunities rotating.
The entire pharmaceutical sector has surged sharply; what happened?
On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.
Stirling : very strong support.
Samleecomp OP : Strong buy volume in recent move. Potentially Uptrend can continue